Glycylglycine (Gly-Gly), the simplest synthetic dipeptide, is mainly divided into industrial bulk grade, food nutrition grade, cell culture and pharmaceutical reagent grade, with drastically differentiated pricing rules for different purities and order batches. Its full-year price trend in 2026 shows a pattern of mild Q1 fluctuation, slight cost-driven Q2 uptick, stable adjustment in Q3, and seasonal softening in Q4, jointly shaped by upstream glycine supply, solvent cost swings, downstream biotech demand, domestic environmental supervision and export order cycles.
1. Core cost fundamentals determining 2026 price operation
Glycine serves as the exclusive raw material for glycylglycine synthesis, dominating over 65% of total production cost. In 2026, new glycine production lines in Northwest China were fully launched in Q1, lifting national glycine supply by 7.2% year-on-year and forming an oversupplied buyer's market, which suppressed the room for sharp rises of Gly-Gly bulk prices throughout the year. Meanwhile, polar solvents including DMF and dichloromethane, key for condensation and purification, maintained high average prices inherited from 2025 due to continuous strict environmental rectification, adding a fixed 8%-9% extra unit cost for all glycylglycine manufacturers and forming a permanent cost floor that prevents steep price slumps even with sufficient glycine supply.
Labor, energy and purification expenses for high-purity grades constitute another pricing dividing line. Bulk industrial Gly-Gly only requires simple recrystallization, while cell culture and pharmaceutical grades demand multi-stage fine filtering, low-temperature decolorization and heavy metal removal; the processing gap widens price disparities by 3-10 times between bulk and lab reagent specifications.
2. Quarterly price fluctuation trajectory in 2026
Q1 2026: Inventory clearing, slight downward pressure
At the start of the year, major domestic manufacturers carried over large inventories accumulated in late 2025's weak export season. Downstream biopharma and lab research clients suspended centralized procurement before the Spring Festival holiday, dragging market trading volume down.
Bulk food/industrial grade (98%, 1-ton minimum order): Factory offers dipped to USD 34.5-41.5/kg, down 3%-5% month-on-month compared to late 2025.
Small-batch reagent grade (99%, 1-25 kg packages): Retail quotations stayed steady without obvious cuts, as lab demand remained rigid and scattered small orders supported premium pricing.
Near the end of Q1, pharmaceutical intermediate factories resumed raw material stocking, digesting excess factory inventory and halting further price declines.
Q2 2026: Cost pull triggers moderate price rebound
Two factors pushed glycylglycine prices upward from April to June 2026. First, national environmental inspections tightened across East China's chemical industrial parks, limiting temporary production loads of small and medium Gly-Gly factories and tightening spot bulk supply. Second, solvent prices rebounded 6%-11% amid tight supply of chemical auxiliary materials, lifting overall synthesis costs.
Bulk industrial 98% grade spot prices climbed to USD 38-46/kg by mid-June, an average 10% rise from Q1 lows; long-term contract clients secured 3%-5% preferential prices via quarterly fixed orders.
High-purity cell culture grade (≥99.5%) saw a mild 6% quotation increase, driven by growing demand for peptide buffer raw materials in cell therapy and in vitro diagnostic reagent production. Export inquiries from Southeast Asia and North American biotech firms rose month-on-month, further supporting price stability of high-end grades. As of June 2026, mainstream Chinese bulk manufacturers maintained stable spot quotations without speculative sharp hikes, restrained by adequate glycine raw material output.
Q3 2026: Supply-demand rebalancing, narrow price consolidation
Q3 will enter the traditional production peak for amino acid derivatives, as manufacturers ramp up operating rates to replenish mid-to-late year inventory. Sufficient glycine supply offsets solvent cost pressure, and prices will enter a narrow consolidation range with limited ups and downs.
Bulk grade prices are projected to fluctuate within USD 37-45/kg; the upward momentum from Q2 will fade, as newly released glycine capacity suppresses raw material cost surges. Demand remains balanced: steady orders from cosmetic peptide additives and plant growth promoter manufacturers offset periodic slowdowns in biotech research procurement. No large-scale price surge or collapse is expected in this quarter.
Q4 2026: Seasonal destocking, marginal price decline
Entering October-December, downstream buyers reduce year-end inventory to cut capital occupation, while manufacturers release year-end promotional offers to clear annual output. The full-year price trend will end with a slight softening.
Bulk industrial grade prices are forecast to retreat 4%-7% from Q3 peaks, falling back to USD 35-42/kg. High-purity pharmaceutical and cell culture grades will resist deep declines due to rigid annual research and production demand, with only 2%-4% minor concessions for annual framework contracts. Export shipments will maintain steady volume to hedge domestic destocking pressure and avoid extreme price slumps.
3. Grade-based permanent price differentiation throughout 2026
Purity and packaging batch remain the most decisive factors for price gaps, with tiered pricing maintained across all four quarters:
Industrial/food bulk grade (98%, 25kg drum, ton-level order): USD 34.5-46/kg, the most volatile segment sensitive to glycine and solvent costs.
Nutritional additive grade (99%, 25kg food-grade drum): A 15%-25% premium over industrial grade, stable demand from oral beauty and pet nutrition formulations limits price volatility.
Cell culture/pharmaceutical reagent grade (≥99.5%, small bottle packaging, 100g-1kg): USD 260-1,230/kg, with minimal fluctuation, supported by rigid high-value biotech downstream demand.
Lab analytical standards and high-purity reference samples retain ultra-high retail premiums unaffected by bulk raw material cycles.
4. Long-term influencing factors sustaining 2026's mild fluctuation pattern
First, supply-side balance restrains drastic price swings. New glycine capacity expansion guarantees stable low-cost raw material supply, while limited new glycylglycine production lines prevent oversupply of finished products, forming a balanced supply framework that rules out skyrocketing prices.
Second, demand growth is incremental rather than explosive. Emerging applications including oral beauty peptides, plant growth regulators and pet nutrition additives deliver steady annual demand growth of 6%–9%, without short-term order surges that trigger price spikes.
Third, cost rigidities create a price bottom. Persistently high solvent, environmental treatment and purification costs eliminate room for substantial price drops; manufacturers will suspend low-margin production before offering steep discounts.
Fourth, export markets act as a buffer. European, American and Southeast Asian biotech clients provide continuous overseas orders, offsetting domestic seasonal procurement fluctuations and smoothing full-year price volatility.
5. Full-year 2026 price summary
For the whole year of 2026, glycylglycine prices will operate in a moderate band without sharp bull or bear cycles. Bulk industrial/food grade prices range from USD 34.5-46/kg, experiencing Q1 decline, Q2 cost-driven rise, Q3 consolidation and Q4 seasonal softening. High-purity pharmaceutical and cell culture reagent grades maintain stable premium quotations with only minor quarterly adjustments. Compared with 2025’s overall average, 2026's annual mean bulk price will rise roughly 4%-6%, mainly attributed to sustained high organic solvent and environmental compliance costs, partially counterbalanced by sufficient glycine raw material supply.
